Article
Impact of genetic variation in breast cancer resistance protein (BCRP/ABCG2) on sunitinib pharmacokinetics.
Drug metabolism and pharmacokinetics - 1 Jan 2012
Mizuno Tomoyuki, Fukudo Masahide, Terada Tomohiro, Kamba Tomomi, Nakamura Eijiro, Ogawa Osamu, Inui Ken-Ichi, Katsura Toshiya
Abstract excerpt
To elucidate the impact of genetic variations in breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (MDR1/ABCB1) on the pharmacokinetics of sunitinib, we carried out a pharmacogenetic study in a clinical setting and pharmacokinetic analysis using Abcg2(-/-), Abcb1a/1b(-/-) and Abcb1a/1b;Abcg2(-/-) mice. Nineteen renal cell carcinoma patients were enrolled in this study. The plasma concentrations of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
